High-oxygen gas-permeable culture improves viability and supports quantitative antifibrotic pharmacology in precision-cut liver slices

  • Am J Physiol Gastrointest Liver Physiol. 2026 Aug 1;331(2):G216-G228. doi: 10.1152/ajpgi.00144.2026.
Yusaku Komoike  1 Hideyuki Hiyoshi  1 Teruyoshi Yamashita  1 Shinsuke Araki  1
Affiliations
  • 1. R&D Research, Global Advanced Platform, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Abstract

Liver fibrosis remains a major unmet medical need, and quantitative evaluation of antifibrotic candidates requires ex vivo models that preserve tissue function while supporting higher-throughput pharmacological testing. Precision-cut liver slices (PCLSs) maintain native multicellular architecture but are limited by suboptimal oxygenation and insufficient throughput, particularly in fibrotic tissue. Therefore, we aimed to establish a high-oxygen culture system using commercially available gas-permeable plates to enable quantitative antifibrotic testing in rat PCLSs. Normal and choline-deficient high-fat diet-induced fibrotic PCLSs were cultured under 20% or 80% O2 in gas-permeable (G-Rex; NOK, InnoCell) or conventional nongas-permeable formats. High-oxygen gas-permeable conditions improved viability, assessed by cumulative Lactate Dehydrogenase release, and enhanced hepatic function, including albumin secretion and glycogen preservation. Under optimized conditions, transforming growth factor-β1 and platelet-derived growth factor-BB markedly induced Col1a1 and Acta2 expression and increased Collagen type I production. Fibrotic PCLSs maintained activated stellate cell features and sustained Collagen secretion for 96 h. This platform enabled quantitative pharmacological profiling: the activin receptor-like kinase 5 (ALK5) inhibitor SB-525334 consistently suppressed fibrogenic gene expression and Collagen production, whereas the multikinase inhibitor nintedanib showed weaker inhibition. Miniaturization to gas-permeable 96-well plates preserved functional and pharmacological performance, increasing experimental yield per liver. Overall, this accessible, high-oxygen PCLS system overcomes oxygenation limitations and enables reliable, medium-throughput antifibrotic testing in a physiologically intact ex vivo fibrosis model.NEW & NOTEWORTHY Precision-cut liver slices preserve native hepatic architecture but are difficult to maintain and miniaturize for quantitative drug testing, particularly in fibrotic tissue. High-oxygen culture using readily available gas-permeable plates improves viability and hepatocyte function while sustaining fibrogenic readouts, enabling concentration-response antifibrotic testing in 96-well formats. This medium-throughput workflow increases data yield per liver and provides a practical, consistent platform for antifibrotic evaluation.

Keywords
antifibrotic pharmacology; gas-permeable culture; high-throughput assay; liver fibrosis; precision-cut liver slice (PCLS).
Products